Ultimately, our data suggest that truncated PPM1D enhances abnormal growth of t-AML, and inhibition of PPM1D may represent a promising treatment strategy for a fraction of therapy-induced leukemias. The gene discussed is PPM1D; the disease is acute myeloid leukemia.